Endothelial Progenitor Cells as a Therapeutic Option in Peripheral Arterial Disease.
EUR J VASC ENDOVASC
475 - 481.
Background: Endothelial progenitor cells (EPC) are a subpopulation of bone-marrow mononuclear cells that are capable of generating new blood vessels in areas of ischaemia or infarction. This review examines the regenerative potential of EPC to ameliorate peripheral ischaemia.Methods: An online search was done using OVID Medline Search, PubMed, and Cochrane Review Database, for all reviews and original articles in English concerning progenitor or bone-marrow mononuclear cells.Results and conclusion: There are many controversies in EPC research, especially in the areas of identification, characterization, and therapeutic use. Both animal and human studies have shown benefits from using EPC to combat peripheral arterial and cerebrovascular disease. To bring EPC into wider clinical use, larger controlled clinical trials and better methods of augmenting EPC function and lifespan are required. Until then EPC should be used under robust trial conditions with ethical approval. (c) 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
|Title:||Endothelial Progenitor Cells as a Therapeutic Option in Peripheral Arterial Disease|
|Keywords:||Progenitor cells, Stem cell therapy, Ischaemia, Peripheral arterial disease, MARROW MONONUCLEAR-CELLS, UMBILICAL-CORD BLOOD, LIMB ISCHEMIA, GROWTH-FACTOR, AUTOLOGOUS TRANSPLANTATION, CARDIOVASCULAR RISK, HEART-DISEASE, STEM-CELLS, ANGIOGENESIS, IMPLANTATION|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Surgery and Interventional Science (Division of)|
Archive Staff Only